PRLD — Prelude Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $236.22m
- $84.47m
- $12.14m
Brief: Prelude Therapeutics Q2 Loss Per Share $0.58
Brief: Prelude Therapeutics Announces Appointment Of Martin Babler To Board
Prelude Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Prelude Therapeutics Posts Q1 Loss Per Share $0.47
Brief: Prelude Therapeutics Announces Fourth Quarter And Full Year 2020 Financial Results And Provides Operational Update
Brief: Prelude Therapeutics Announces Pricing Of Upsized Public Offering
Generation Bio slumps as co plans equity raise ahead of JP Morgan conference
Brief: Prelude Expects To Report Cash And Cash Equivalents Of $218.3 Million As Of Dec. 31
Brief: Prelude Files For Offering Of Up To 1.75 Million Shares
Brief: Prelude Therapeutics Announces Third Quarter 2020 Financial Results
Brief: Prelude Announces Dosing Of First Patient In Phase 1 Trial Of Mcl1 Inhibitor PRT1419
PMV Pharmaceuticals: Doubles in Nasdaq debut
Prelude Therapeutics: Jumps 33% in Nasdaq debut
Brief: Prelude Therapeutics Shares Open 32.8% Above IPO Price In Debut On Nasdaq
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:01 AM
Brief: Prelude Therapeutics Announces Pricing Of Initial Public Offering